Cellectar Biosciences, Inc. (CLRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLRB Stock Price Chart Interactive Chart >
CLRB Price/Volume Stats
| Current price | $1.54 | 52-week high | $7.90 |
| Prev. close | $1.49 | 52-week low | $1.25 |
| Day low | $1.48 | Volume | 32,220 |
| Day high | $1.57 | Avg. volume | 45,029 |
| 50-day MA | $1.69 | Dividend yield | N/A |
| 200-day MA | $3.56 | Market Cap | 14.45M |
Cellectar Biosciences, Inc. (CLRB) Company Bio
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is based in Madison, Wisconsin.
Latest CLRB News From Around the Web
Below are the latest news stories about CELLECTAR BIOSCIENCES INC that investors may wish to consider to help them evaluate CLRB as an investment opportunity.
Cellectar Biosciences Announces Shane Lea as Chief Commercial OfficerFLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior |
Cellectar Biosciences (CLRB) Receives a Buy from Maxim GroupMaxim Group analyst Jason McCarthy maintained a Buy rating on Cellectar Biosciences (CLRB - Research Report) yesterday and set a price target of $7.00. The company's shares opened today at $1.90.According to TipRanks, McCarthy is an analyst with an average return of -37.8% and a 14.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cellectar Biosciences with a $7.67 average price target. |
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC ConferencePreclinical data demonstrate ability to deliver targeted alpha-emitting isotopes to malignant cells and therapeutic efficacyFLORHAM PARK, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the presentation of preclinical data at the 13th Annual World ADC Conference supporting development of CLR 12120 ser |
Cellectar Announces Resolution of Breach of Contract and Intellectual Property DisputeSecures license to the patents at issue in the lawsuitFLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that Cellectar Biosciences, Inc., Wisconsin Alumni Research Foundation, and Drs. Jamey Weichert and Anatoly Pinchuk have resolved a lawsuit filed by Cellectar in October 2021 in the United States Di |
Cellectar Biosciences (CLRB) Investor Presentation - Slideshow (NASDAQ:CLRB)The following slide deck was published by Cellectar Biosciences, Inc. |
CLRB Price Returns
| 1-mo | -3.75% |
| 3-mo | -26.67% |
| 6-mo | -60.71% |
| 1-year | -70.38% |
| 3-year | -94.38% |
| 5-year | -98.75% |
| YTD | -9.94% |
| 2022 | -74.25% |
| 2021 | -68.08% |
| 2020 | -7.56% |
| 2019 | 45.16% |
| 2018 | -88.69% |
Loading social stream, please wait...